Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 307Recurrence 64Neoplasms 32Neoplasms, Plasma Cell 17Lymphoma, Non-Hodgkin 14Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Vomiting 11Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Nausea 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Ovarian Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Hematologic Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Paraproteinemias 5Lung Neoplasms 5Leukemia 5Small Cell Lung Carcinoma 4Renal Insufficiency 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Plasmacytoma 4Lymphoma, Follicular 4Hematologic Diseases 4Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3

Interventions

niraparib 1Trabectedin 1Ocoxin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adnexal Diseases × Dexamethasone × Clear all
NCT00050414 2013-01-10

A Study of Trabectedin in Patients With Advanced Ovarian Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
147 enrolled
Gynecologic

Adnexal Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡